These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 3297319)

  • 41. Drenching sweats as an off phenomenon in Parkinson's disease: treatment and relation to plasma levodopa profile.
    Sage JI; Mark MH
    Ann Neurol; 1995 Jan; 37(1):120-2. PubMed ID: 7818245
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Placebo-controlled study of mesulergine in Parkinson's disease.
    Jankovic J; Orman J; Jansson B
    Neurology; 1985 Feb; 35(2):161-5. PubMed ID: 3881692
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The therapy of wearing-off].
    Murata M
    Nihon Rinsho; 2004 Sep; 62(9):1716-9. PubMed ID: 15462390
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dopaminergic agonists in the treatment of Parkinson's disease.
    Goetz CG; Diederich NJ
    Neurol Clin; 1992 May; 10(2):527-40. PubMed ID: 1350052
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Early introduction of dopamine agonists in the long-term treatment of Parkinson's disease.
    Ogawa N
    Neurology; 1998 Aug; 51(2 Suppl 2):S13-20. PubMed ID: 9711975
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of young-onset Parkinson's disease: role of dopamine receptor agonists.
    Kostić VS
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S71-5. PubMed ID: 20123561
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dopamine agonists in Parkinson's disease.
    Calne DB; Burton K; Beckman J; Martin WR
    Can J Neurol Sci; 1984 Feb; 11(1 Suppl):221-4. PubMed ID: 6231979
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mesulergine in early Parkinson's disease: a double blind controlled trial.
    Dupont E; Mikkelsen B; Jakobsen J
    J Neurol Neurosurg Psychiatry; 1986 Apr; 49(4):390-5. PubMed ID: 3517235
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mesulergine and pergolide in previously untreated Parkinson's disease.
    Wright A; Lees AJ; Stern GM
    J Neurol Neurosurg Psychiatry; 1987 Apr; 50(4):482-4. PubMed ID: 3585362
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dopamine agonists and their role in Parkinson's disease treatment.
    Tan EK
    Expert Rev Neurother; 2003 Nov; 3(6):805-10. PubMed ID: 19810883
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dopamine agonists and ischemic complications in Parkinson's disease: a nested case-control study.
    Arbouw ME; Movig KL; Guchelaar HJ; Neef C; Egberts TC
    Eur J Clin Pharmacol; 2012 Jan; 68(1):83-8. PubMed ID: 21779969
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lisuride, a dopamine agonist in the treatment of early Parkinson's disease.
    Rinne UK
    Neurology; 1989 Mar; 39(3):336-9. PubMed ID: 2927639
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lisuride in Parkinson disease: efficacy of lisuride compared to levodopa.
    Lieberman A; Goldstein M; Neophytides A; Kupersmith M; Leibowitz M; Zasorin N; Walker R; Kleinberg D
    Neurology; 1981 Aug; 31(8):961-5. PubMed ID: 7022259
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cabergoline : a review of its use in the treatment of Parkinson's disease.
    Curran MP; Perry CM
    Drugs; 2004; 64(18):2125-41. PubMed ID: 15341508
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative efficacy of two dopamine agonists, pergolide and lergotrile, in Parkinson disease.
    Lieberman AN; Goldstein M; Leibowitz M
    N Y State J Med; 1988 Aug; 88(8):420-2. PubMed ID: 2902541
    [No Abstract]   [Full Text] [Related]  

  • 56. Pergolide. A review of its pharmacological properties and therapeutic potential in Parkinson's disease.
    Langtry HD; Clissold SP
    Drugs; 1990 Mar; 39(3):491-506. PubMed ID: 2184010
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Differentiation of dopamine agonists and their role in the treatment of Parkinson's disease.
    Calne DB
    J Neural Transm Suppl; 1999; 56():185-92. PubMed ID: 10370912
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Therapeutic effect of lisuride in advanced Parkinson's disease.
    Meneghetti G; Bracco F; Giometto B; Ferla S; Schergna E
    Eur Neurol; 1986; 25(1):74-80. PubMed ID: 3510126
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Therapeutic experience with the new dopamine agonist CU 32-085 in advanced Parkinson's disease.
    Biesemeyer H; Ludin HP; Ringwald E
    J Neurol; 1983; 230(1):19-23. PubMed ID: 6194269
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of pergolide mesylate, an ergoline, in animal models of Parkinson's disease: implications for therapy.
    Koller WC; Diamond BI; Weiner WJ; Nausieda PA; Klawans HL
    Trans Am Neurol Assoc; 1979; 104():161-4. PubMed ID: 553398
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.